Maurice T, Vignon J
INSERM U 336, Ecole Nationale Supérieure de Chimie, Montpellier, France.
J Neurosci Res. 1990 Jul;26(3):377-85. doi: 10.1002/jnr.490260315.
The phencyclidine (PCP) derivative N-[1-(2-thienyl)cyclohexyl]-piperidine (3H-TCP) was used to label in vivo the N-methyl-D-aspartate (NMDA) receptor-associated ionic channel in the mouse brain. After the injection of a tracer dose of 3H-TCP, a spread labeling throughout the brain was observed, but was the highest in the cerebellum. Preadministration of unlabeled TCP (30 mg/kg) resulted in a 90% reduction of 3H-TCP binding. PCP, TCP, MK-801, dexoxadrol, ketamine, and SKF 10,047 isomers dose-dependently prevented the in vivo 3H-TCP binding. ID50 determined in the cerebrum and the cerebellum were respectively correlated with K0.5 for 3H TCP high (rat cortex) and low affinity (rat cerebellum) sites in vitro. The pharmacological specificity of the 3H-TCP binding site in the cerebellum was significantly different from that in the cerebrum. ID50 values were generally higher than in the cerebrum and, particularly, MK-801, the most potent drug in the cerebrum, was without significant effect in the cerebellum, at any time and at doses as high as 30 mg/kg. N-[1-(2-benzo(b) thiophenyl)cyclohexyl]piperidine (BTCP), desipramine, and atropine showed a more efficient prevention of 3H-TCP binding in the cerebellum than in the cerebrum. The prevention of the binding by TCP or PCP, at doses close to their ID50 values, was rapid and then decreased slowly. The effect of MK-801 was long-lasting. This study confirm previous in vitro studies: 3H-TCP is an efficient tool for the labeling of the NMDA receptor-associated ionic channel.(ABSTRACT TRUNCATED AT 250 WORDS)
苯环己哌啶(PCP)衍生物N-[1-(2-噻吩基)环己基]-哌啶(3H-TCP)被用于在小鼠大脑中对与N-甲基-D-天冬氨酸(NMDA)受体相关的离子通道进行体内标记。注射示踪剂量的3H-TCP后,观察到其在整个大脑中呈弥散性标记,但在小脑中含量最高。预先给予未标记的TCP(30毫克/千克)可使3H-TCP结合减少90%。PCP、TCP、MK-801、右吗拉胺、氯胺酮和SKF 10,047异构体呈剂量依赖性地阻止3H-TCP的体内结合。在大脑和小脑中测定的半数抑制剂量(ID50)分别与体外3H-TCP高亲和力(大鼠皮层)和低亲和力(大鼠小脑)位点的半数解离常数(K0.5)相关。小脑中3H-TCP结合位点的药理学特异性与大脑中的显著不同。ID50值通常高于大脑中的,特别是在大脑中最有效的药物MK-801,在小脑的任何时间及高达30毫克/千克的剂量下均无显著作用。N-[1-(2-苯并(b)噻吩基)环己基]哌啶(BTCP)、地昔帕明和阿托品在小脑中比在大脑中更有效地阻止3H-TCP结合。TCP或PCP在接近其ID50值的剂量下对结合的阻止作用迅速,然后缓慢下降。MK-801的作用持久。本研究证实了先前的体外研究:3H-TCP是标记与NMDA受体相关离子通道的有效工具。(摘要截短于250字)